Sign in

    Joe Catanzaro

    Director and Senior Biotech Equity Analyst at Piper Sandler

    Joe Catanzaro is a Director and Senior Biotech Equity Analyst at Piper Sandler, specializing in biotechnology sector research with coverage of companies such as those in the biopharma and biotech industries. He has delivered investment calls on firms with high upside targets, though his performance metrics show a 36.71% success rate and an average return of -7.69%. Catanzaro joined Piper Sandler in 2018 and previously held biotech analyst roles, leveraging deep expertise in healthcare equities. He holds professional credentials in line with industry standards, including FINRA registration and securities licenses.

    Joe Catanzaro's questions to CytomX Therapeutics (CTMX) leadership

    Joe Catanzaro's questions to CytomX Therapeutics (CTMX) leadership • Q4 2024

    Question

    Inquired about the number of CX-2051 dose cohorts considered to be within the therapeutically active range and whether differential activity is expected based on patient characteristics like KRAS status or liver metastases.

    Answer

    A significant number of patients in the upcoming CX-2051 data release will have received doses within the predicted therapeutic range, which starts from dose level 3. The company is not expecting differential activity based on KRAS status or liver mets but is enrolling a broad population to assess this.

    Ask Fintool Equity Research AI

    Joe Catanzaro's questions to AADI leadership

    Joe Catanzaro's questions to AADI leadership • Q1 2024

    Question

    Sought clarification on the FYARRO sales 'cannibalization' by the PRECISION1 trial, asked about the baseline characteristics of the full PRECISION1 cohort, and inquired about the reason for terminating the Mirati collaboration.

    Answer

    The company clarified that 'cannibalization' refers to non-PEComa patients potentially being enrolled in the PRECISION1 trial instead of receiving commercial FYARRO off-label. They confirmed the PRECISION1 population seems consistent so far and stated the Mirati collaboration was terminated for strategic and financial reasons, not due to trial data.

    Ask Fintool Equity Research AI

    Joe Catanzaro's questions to I-Mab (IMAB) leadership

    Joe Catanzaro's questions to I-Mab (IMAB) leadership • H1 2023

    Question

    Joe Catanzaro asked about givastomig's potential to treat a broader range of Claudin 18.2 expression levels and questioned the clinical strategy for lemzoparlimab in China following the trial failure of a competitor's CD47 agent.

    Answer

    CMO John Hayslip explained that early data suggests givastomig is effective even in tumors with low Claudin 18.2 expression. Regarding lemzoparlimab, CEO Raj Kannan stated that it is premature to make a decision, as they believe their molecule is differentiated. The company will review interim data and class data in H1 2024 before deciding on the next steps.

    Ask Fintool Equity Research AI

    Joe Catanzaro's questions to I-Mab (IMAB) leadership • Q4 2021

    Question

    Joe Catanzaro requested high-level details on the upcoming Phase 2 uliledlimab data, including patient numbers, tumor types, and biomarker analysis, and also asked about the company's expectations for executing a global licensing collaboration for the program.

    Answer

    Andrew Zhu, President, confirmed an abstract was submitted to ASCO with safety data from over 90 patients and efficacy data from over 40 evaluable patients, primarily in non-small cell lung cancer, with plans to analyze biomarkers like CD73 and PD-L1. Jingwu Zang, Founder, Chairman and Acting CEO, added that since the CD73 drug class is still early, more data is needed to facilitate ongoing partnership discussions with two or three large pharma groups.

    Ask Fintool Equity Research AI

    Joe Catanzaro's questions to Rain Enhancement Technologies Holdco (RAIN) leadership

    Joe Catanzaro's questions to Rain Enhancement Technologies Holdco (RAIN) leadership • Q2 2023

    Question

    Joe Catanzaro from Piper Sandler asked if the company had identified any potential reasons for milademetan's underperformance in the MANTRA trial compared to previous data.

    Answer

    CSO Robert Doebele stated that the company would address the trial results and provide a detailed analysis during planned presentations at a medical conference in the fourth quarter of the year.

    Ask Fintool Equity Research AI

    Joe Catanzaro's questions to Rain Enhancement Technologies Holdco (RAIN) leadership • Q1 2023

    Question

    Joe Catanzaro of Piper Sandler questioned the expected level of disclosure for the MANTRA top-line results, including PFS, hazard ratio, and p-values. He also asked about the preclinical mechanism of cooperativity for the MEK inhibitor combination.

    Answer

    CEO Avanish Vellanki stated that the level of disclosure for the top-line data will be decided upon data review. CSO Robert Doebele detailed two potential mechanisms for the MEK inhibitor synergy, involving ARC's effect on MDM2 and p53, and noted this rationale could extend to other TKI therapies.

    Ask Fintool Equity Research AI

    Joe Catanzaro's questions to Connect Biopharma Holdings (CNTB) leadership

    Joe Catanzaro's questions to Connect Biopharma Holdings (CNTB) leadership • Q2 2022

    Question

    Joe Catanzaro of Piper Sandler asked for confirmation that the global Phase 3 atopic dermatitis program would launch by year-end regardless of a partnership, and inquired about the level of detail planned for the October top-line data release.

    Answer

    Co-Founder and CEO Dr. Zheng Wei confirmed the company plans to launch the global Phase 3 study before year-end using its current financial resources, independent of securing a partner by then. Chief Medical Officer Dr. Chin Lee stated that the October top-line release will be detailed, including the primary endpoint, key secondary endpoints, and safety data, aiming to provide more granularity than previous high-level announcements.

    Ask Fintool Equity Research AI